Three ent-kaurane diterpenes (1-3), four lupane-triterpene glycosides (4-7), and an oleanane-triterpene glycoside (8) were isolated from the ethyl acetate and water extracts of the steamed leaves of Acanthopanax koreanum using a combination of various column chromatographies. The structures of the isolates were determined by 1 H-, 13 C-NMR spectroscopy and mass spectrometry. To investigate the biological effects of the eight compounds (1-8) on peroxisome proliferator-activated receptor gamma (PPARγ), luciferase reporter assays were used. Among the tested compounds, ent-kaur-16-en-19-oic acid (1), 16-hydroxy-ent-kauran-19-oic acid (2), and 17-hydroxy-ent-kaur-15-en-19-oic acid (3) showed considerable effects on PPARγ activity, compared with the positive control, troglitazone. To evaluate specificity and sensitivity of the active compounds (1-3) in the regulation of transactivation of PPARs, Gal4-PPARs-LBD luciferase reporter assays were examined. In this study, the three ent-kaurane diterpenes (1-3) were found to up-regulate PPARand PPAR activities, whereas they did not activate PPAR activity.
Peroxisome-proliferator activated receptors (PPARs) are members of the nuclear receptor gene family that are activated by fatty acids and fatty acid metabolites [1] . The crucial role that PPAR receptors play in the regulation of metabolism makes them inviting targets for the treatment of diabetes mellitus, atherosclerosis, and obesity [2] . The PPARs are comprised of three subtypes, PPAR, PPAR and PPARδ/ [3] . Recently, extensive research has been reported that the designed, synthesized and characterized PPARdual agonists improve insulin sensitivity and reverse hyperglycemia with minimized weight gain in preclinical models of type 2 diabetes [2] . However, nothing has been reported about either the extracts or components from Acanthopanax koreanum Nakai regarding PPARs activity.
A. koreanum (Araliaceae) is an indigenous shrub, commonly used as a folk medicine in South Korea for tonic and sedative effects, as well as for its gingseng-like activity [4] . The roots and stem bark of the plant have been used for treating rheumatoid arthritis, hepatitis, and diabetes in oriental medicine [5] .
In oriental medicines, the herbal material has been processed to enhance its preservation and improve the efficacy by steaming at high temperature and pressure. To induce the chemical changes and enhance the biological activities of the plant, the leaves of A. koreanum were processed as previously reported [6] . Herein, we report the isolation of the components from the steamed leaves of A. koreanum and evaluation of their effects on PPARs activity.
Three ent-kaurane diterpenes (1-3), four lupane-triterpene glycosides (4-7), and an oleanane-triterpene glycoside (8) were isolated from the ethyl acetate and water extracts of the steamed leaves of A. koreanum using a combination of silica gel, Diaion HP-20, and YMC RP-18 column chromatography. Compounds 1-8 were identified as entkaur-16-en-19-oic acid (1) [7] , 16-hydroxy-ent-kauran-19-oic acid (2) [8] , 17-hydroxy-ent-kaur-15-en-19-oic acid (3) [7] , acankoreoside A (4) [9] , acankoreoside D (5) [9] , acantrifoside A (6) [9] , acankoreoside E (7) [10] , and gypsogenin 28-O--L-rhamnopyranosyl-(14)--Dglucopyranosyl(16)--D-glucopyranoside (8) [11] , respectively ( Figure 1 ).
To evaluate the modulated PPAR activity of the isolated compounds (1-8), a nuclear transcription PPRE cellreporter system was used. The PPAR-responsive luciferase construct encodes the firefly luciferase reporter gene under the control of a minimal CMV promoter and tandem repeats of the PPRE gene. The number of response elements and the intervening sequence between these response elements has been experimentally optimized to maximize the signal-to-noise ratio. This construct monitors both increases and decreases in the transcriptional activity of PPAR and can be used to monitor and determine the effect of compounds on PPAR activity. Activated PPAR binds the PPRE, which is located in the promoter of a luciferase gene, and activates the transcription of the reporter gene. Troglitazone, a well-known PPARγ agonist, was used as a positive control. HepG2 cells were co-transfected with the PPRE luciferase reporter and the PPARγ expression plasmids. Compounds and troglitazone were added to the 0.5% FBS/DMEM culture medium 24 h after transfection. To measure the luciferase activity, cells were lysed 24 h later. As shown in Figure 2 , compounds 1-3 were found to activate the transcription of the PPRE luciferase with EC 50 values of 13.4, 2.4, and 3.7 M, respectively while the positive control, troglitazone, showed an EC 50 value of 2.7 M ( Figure 2 ). To confirm the effects of PPAR activity of the tested compounds, cell viability was simultaneously determined using a colorimetric MTS assay (Promega, Madison, WI). All of the isolates (1-8) exhibited either little or no effect at the concentration tested ( Figure 3 ).
To evaluate specificity and sensitivity of compounds 1-3 in the regulation of transactivation of PPARs, Gal4-PPARs-LBD luciferase reporter assays were examined. The cells were co-transfected with one of the pFA-Gal4-PPAR-LBDs together with pFR-Luc and then treated with test samples and each positive control. Interestingly, the compounds activated PPAR ( Figure 4B ) and PPAR ( Figure 4C ), whereas they did not activate PPAR ( Figure  4A ). All three compounds showed a dose-dependent manner to upregulate PPARand PPAR as a partial agonist, compared with the positive control, L-165,041 and troglitazone, respectively. These results indicate that compounds 1-3 act as a potential and selective dual agonist for PPAR through interaction with their LBD domain.
There have been some reports on PPAR dual agonists as a beneficial combination therapy for type 2 diabetes [3] . A combination of PPAR dual agonists could reduce blood glucose levels and increase insulin sensitivity, simultaneously improving the dyslipidemia in diabetic patients [12] . In addition, PPAR dual agonists are still under development to prevent and inhibit progression of diabetic complications [2] . These findings are supportive of the current study, in which compounds 1-3 were shown to transactivate both PPARand PPAR. Thus, the present study suggests that ent-kauran-type diterpenes (1-3) isolated from A. koreanum may be potential agents targeting insulin resistance and related metabolic disorders through activation of PPARand PPAR. 
Experimental
General procedure: Optical rotations were measured with a DIP-360 digital polarimeter (Jasco, Easton, MD, USA). NMR spectra were obtained at room temperature on a Bruker DRX 400 NMR spectrometer with tetramethylsilane (TMS) as internal standard. Fast atom bombardment mass spectrometry (FABMS) measurements utilized a JMS-T100TD spectrometer (Tokyo, Japan). Column chromatography was carried out on silica gel (70-230 and 230-400 mesh, Merck, Darmstadt, Germany), YMC RP-18 resins (30-50 mm, Fuji Silysia Chemical Ltd., Aichi, Japan), and HP-20 Diaion (Mitshubishi Chemical, Tokyo, Japan). Analytical thin-layer chromatography (TLC) was performed on either Kieselgel 60 F 254 or RP-18 F 254 s (Merck, Darmstadt, Germany) glass plates and compounds were visualized by spraying with 10% aqueous H 2 SO 4 solution, followed by heating.
Plant material:
The leaves of Acanthopanax koreanum Nakai (Araliaceae) were collected in Susin Ogapi, Cheonan city, Korea, in August 2006 and taxonomically identified by one of authors (Prof. Young Ho Kim). A voucher specimen (CNU 060810) was deposited at the Herbarium of the College of Pharmacy, Chungnam National University, Korea.
Extraction and isolation:
The leaves of A. koreanum (4.0 kg) were processed at 120 o C for 4 h under 0.15 MPa pressure, without mixing with water, to give the steamed sample. The steamed leaves of A. koreanum were extracted with MeOH 3 times under reflux for 15 h to yield 825 g of a dark solid extract, which was suspended in water and then partitioned with n-hexane and ethyl acetate to give n-hexane-soluble (181 g), ethyl acetate-soluble (104 g), and water-soluble fractions (540 g), respectively. The ethyl acetate extract (104 g) was subjected to chromatography on a silica gel column eluting with a mixture of n-hexane: EtOAc: MeOH (gradient from 3:1:0, 1:1:0, 0:3:1, 0:2:1, 0:1:1 v/v) to give fractions F1~F18. Fraction F3 (4.5 g) was chromatographed on a YMC RP-18 column using MeOH: H 2 O (9:1 v/v) as an eluent to yield 5 fractions F3A-F3E. Further purification of fractions F3B (360.2 mg) and F3D (550.5 mg) using silica gel columns with n-hexane: EtAOc (4:1, v/v) yielded compounds 3 (37.1 mg) and 1 (24.7 mg). F3C (430.2 mg) was purified by recrystallization from cold MeOH to afford compound 2 (60.0 mg). The water-soluble fraction (540 g) was chromatographed on Diaion HP-20 eluting with H 2 O, 30%, 50%, 80%, and 100% MeOH, successively. The 80% MeOH eluate was subjected to silica gel column chromatography with CHCl 3 : MeOH: H 2 O (9:1:0.17:3:0.5) to give 17 fractions, F1~F17. Fraction 7 (8.2 g) was chromatographed on a YMC RP-18 column with 60% MeOH to obtain 11 fractions, F7A-F7K. F7D (430.2 mg) was purified by silica gel with CHCl 3 : MeOH: H 2 O (7.5:2.5:0.2) to afford compound 5 (110.4 mg). F7J (165.4 mg) was chromatographed on a YMC RP-18 column with 70% MeOH to give 7 (88.0 mg). F7F (1.8 g) and F7H (1.4 g) were purified by silica gel CC with CHCl 3 : MeOH: H 2 O (7.5:2.5:0.2), followed by YMC RP-18 CC with 70% MeOH to obtain 6 (256.3 mg) and 4 (491.8 mg), respectively. Fraction F11 (4.5 g) was chromatographed on a YMC RP-18 column with 70% MeOH and then on silica gel with CHCl 3 : MeOH: H 2 O (7:3:0.5) to give 8 (309.7 mg). The structures of the isolates were identified by a combination of spectroscopic ( 1 H-and 13 C NMR) and mass spectrometric methods, and by comparisons with literature data.
Cell culture: Human hepatocarcinoma HepG2 cells were suspended in DMEM (Invitrogen, Carlsbad, CA) containing 10% heat-inactivated fetal bovine serum (FBS), 100 units/mL penicillin, and 10 g/mL streptomycin, and incubated at 37°C in 5% CO 2 .
PPRE-luciferase assay:
PPRE-Luc plasmids were kindly provided by Dr Kyoon E. Kim (Chungnam National University, Daejeon, Korea). HepG2 cells were seeded at 1.510 5 cells/well in a 12-well plate and grown for 24 h.
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All cells were transfected using Lipofectamine LTX (Invitrogen, Carlsbad, CA), according to the manufacturer's protocol. Luciferase activity was assayed using a LB 953 Autolumat (EG&G Berthold, Nashua, NH), as described previously [13] . Troglitazone, a specific agonist of PPARγ was obtained from Sigma-Aldrich (St. Louis, MO). Results are expressed as relative luciferase activity. Values are means ± S.E.M. of 3 different experiments, in triplicate.
Cytotoxicity assay:
A MTS assay (Promega Celltiter 96-Aqueous One Solution Assay) was used to analyze the effect of compounds on cell viability, as described by the manufacturer (Promega, Madison, WI). Cells were cultured overnight in a 96-well plate (~1×10 4 cells/well). Cell viability was assessed after the addition of compounds at 10 M for 24 h. At 1 h after the addition of 10 μL/well of MTS solution, the amount of the dissolved formazan was measured spetrophotometrically at 490 nm with a microplate reader (Versamax; Molecular Devices). Measurements were performed in triplicate and are representative of at least 2 independent experiments.
Gal4-PPARs-LBD luciferase assay:
The pFA-Gal4-PPAR-LBD, pFA-PPAR-LBD and pFA-PPAR-LBD expression plasmids were provided by Dr Young Yang (Sookmyung Women's University, Seoul, Korea). HepG2 cells were seeded at 1.510 5 cells in 12-wells and grown for 24 h. All cells were transiently co-transfected with one of the expression vectors for pFA-Gal4-PPAR-LBDs, together with pFR-Luc using the WelFect-M GOLD transfection reagent (Welgene, Seoul, Korea), as described by the manufacturer. Following a 24 h incubation, the cells were treated with compounds (0.1, 1.0, and 10 M) and incubated for 20 h. Luciferase assays were performed using a dual-luciferase reporter assay system according to the instructions of the manufacturer (Promega, CA, USA), and the activity was determined in a Microplate luminometer Centro LB 960 (EG&G Berthold, Bad Wildbad, Germany) by measuring light emission for 5 s. Results are expressed as relative luciferase activity. Values are means ± S.E.M. of 3 different experiments, conducted in triplicate.
